Panacea Biotec Pharma Baddi facility gets 9 USFDA observations
Advertisement
Punjab: Panacea Biotec Limited has announced that the Company’s material wholly-owned subsidiary, Panacea Biotec Pharma Limited (“PBPL”) has received nine observations from the United States Food and Drug Administration (USFDA) for the Baddi facility at the end of the inspection.
The inspection was held between October 03, 2023 and October 12, 2023.
"At the end of the inspection, PBPL was issued an ‘FDA Form 483’ with nine (9) observations which are related to improvements in existing procedures and are addressable. PBPL will respond to the US FDA within the stipulated time and work closely with US FDA to close the said observations," Panacea informed in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.